High-Dose PEG-Intron Pharmacokinetic Study in Patients With Melanoma (Study P04831 AM2)
NCT00457418
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
32
Enrollment
INDUSTRY
Sponsor class
Conditions
Melanoma
Interventions
DRUG:
PEG-Intron
Sponsor
Merck Sharp & Dohme LLC